Your browser doesn't support javascript.
loading
Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis.
Jones, Mark G; Andriotis, Orestis G; Roberts, James Jw; Lunn, Kerry; Tear, Victoria J; Cao, Lucy; Ask, Kjetil; Smart, David E; Bonfanti, Alessandra; Johnson, Peter; Alzetani, Aiman; Conforti, Franco; Doherty, Regan; Lai, Chester Y; Johnson, Benjamin; Bourdakos, Konstantinos N; Fletcher, Sophie V; Marshall, Ben G; Jogai, Sanjay; Brereton, Christopher J; Chee, Serena J; Ottensmeier, Christian H; Sime, Patricia; Gauldie, Jack; Kolb, Martin; Mahajan, Sumeet; Fabre, Aurelie; Bhaskar, Atul; Jarolimek, Wolfgang; Richeldi, Luca; O'Reilly, Katherine Ma; Monk, Phillip D; Thurner, Philipp J; Davies, Donna E.
Afiliación
  • Jones MG; NIHR Southampton Biomedical Research Centre, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
  • Andriotis OG; Institute for Lightweight Design and Structural Biomechanics, TU Wien, Getreidemarkt, Austria.
  • Roberts JJ; Synairgen Research Ltd, Southampton, United Kingdom.
  • Lunn K; Synairgen Research Ltd, Southampton, United Kingdom.
  • Tear VJ; Synairgen Research Ltd, Southampton, United Kingdom.
  • Cao L; Pharmaxis Ltd, Frenchs Forest, Australia.
  • Ask K; Department of Medicine, Firestone Institute for Respiratory Health, McMaster University and The Research Institute of St. Joe's Hamilton, Hamilton, Canada.
  • Smart DE; NIHR Southampton Biomedical Research Centre, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
  • Bonfanti A; Aeronautics, Astronautics and Computational Engineering, Faculty of Engineering and the Environment, University of Southampton, Southampton, United Kingdom.
  • Johnson P; Department of Chemistry, Faculty of Natural and Environmental Sciences, University of Southampton, Southampton, United Kingdom.
  • Alzetani A; Institute for Life Sciences, University of Southampton, Southampton, United Kingdom.
  • Conforti F; NIHR Southampton Biomedical Research Centre, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
  • Doherty R; University Hospital Southampton, Southampton, United Kingdom.
  • Lai CY; NIHR Southampton Biomedical Research Centre, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
  • Johnson B; Biomedical Imaging Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
  • Bourdakos KN; NIHR Southampton Biomedical Research Centre, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
  • Fletcher SV; CRUK and NIHR Experimental Cancer Medicine Centre, Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
  • Marshall BG; Department of Chemistry, Faculty of Natural and Environmental Sciences, University of Southampton, Southampton, United Kingdom.
  • Jogai S; Institute for Life Sciences, University of Southampton, Southampton, United Kingdom.
  • Brereton CJ; NIHR Southampton Biomedical Research Centre, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
  • Chee SJ; University Hospital Southampton, Southampton, United Kingdom.
  • Ottensmeier CH; NIHR Southampton Biomedical Research Centre, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
  • Sime P; University Hospital Southampton, Southampton, United Kingdom.
  • Gauldie J; University Hospital Southampton, Southampton, United Kingdom.
  • Kolb M; NIHR Southampton Biomedical Research Centre, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
  • Mahajan S; University Hospital Southampton, Southampton, United Kingdom.
  • Fabre A; CRUK and NIHR Experimental Cancer Medicine Centre, Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
  • Bhaskar A; CRUK and NIHR Experimental Cancer Medicine Centre, Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
  • Jarolimek W; Division of Pulmonary and Critical Care Medicine, University of Rochester School of Medicine and Dentistry, Rochester, United States.
  • Richeldi L; Department of Medicine, Firestone Institute for Respiratory Health, McMaster University and The Research Institute of St. Joe's Hamilton, Hamilton, Canada.
  • O'Reilly KM; Department of Medicine, Firestone Institute for Respiratory Health, McMaster University and The Research Institute of St. Joe's Hamilton, Hamilton, Canada.
  • Monk PD; Department of Chemistry, Faculty of Natural and Environmental Sciences, University of Southampton, Southampton, United Kingdom.
  • Thurner PJ; Institute for Life Sciences, University of Southampton, Southampton, United Kingdom.
  • Davies DE; Department of Histopathology, St. Vincent's University Hospital & UCD School of Medicine, University College Dublin, Dublin, Ireland.
Elife ; 72018 07 03.
Article en En | MEDLINE | ID: mdl-29966587
ABSTRACT
Matrix stiffening with downstream activation of mechanosensitive pathways is strongly implicated in progressive fibrosis; however, pathologic changes in extracellular matrix (ECM) that initiate mechano-homeostasis dysregulation are not defined in human disease. By integrated multiscale biomechanical and biological analyses of idiopathic pulmonary fibrosis lung tissue, we identify that increased tissue stiffness is a function of dysregulated post-translational collagen cross-linking rather than any collagen concentration increase whilst at the nanometre-scale collagen fibrils are structurally and functionally abnormal with increased stiffness, reduced swelling ratio, and reduced diameter. In ex vivo and animal models of lung fibrosis, dual inhibition of lysyl oxidase-like (LOXL) 2 and LOXL3 was sufficient to normalise collagen fibrillogenesis, reduce tissue stiffness, and improve lung function in vivo. Thus, in human fibrosis, altered collagen architecture is a key determinant of abnormal ECM structure-function, and inhibition of pyridinoline cross-linking can maintain mechano-homeostasis to limit the self-sustaining effects of ECM on progressive fibrosis.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Fibrosis Pulmonar / Reticulina / Colágeno / Inhibidores Enzimáticos / Matriz Extracelular / Aminoácido Oxidorreductasas Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Elife Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Fibrosis Pulmonar / Reticulina / Colágeno / Inhibidores Enzimáticos / Matriz Extracelular / Aminoácido Oxidorreductasas Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Elife Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido